NASDAQ:AEMD Aethlon Medical Q1 2027 Earnings Report $0.58 -0.02 (-2.63%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.61 +0.03 (+4.33%) As of 07/24/2026 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aethlon Medical EPS ResultsActual EPSN/AConsensus EPS -$0.79Beat/MissN/AOne Year Ago EPSN/AAethlon Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAethlon Medical Announcement DetailsQuarterQ1 2027Date8/12/2026TimeAfter Market ClosesConference Call DateWednesday, August 12, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Aethlon Medical Earnings HeadlinesAethlon Medical (NASDAQ:AEMD) Stock Price Crosses Below 200-Day Moving Average - Here's WhyJuly 24 at 3:43 AM | americanbankingnews.comAethlon MedicalJuly 13, 2026 | fool.comThis tiny piece of glass could be bigger than GPUsA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it essential for AI to scale, while Sequoia Capital labels it a holy grail. Stocks tied to this technology have already surged 133 percent, 217 percent, and 320 percent in recent months, according to Brownstone Research analyst Jason Bodner, who identified Nvidia at 4.50. | Brownstone Research (Ad)Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®July 13, 2026 | prnewswire.comAethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ RulesJuly 6, 2026 | prnewswire.comAethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®June 26, 2026 | prnewswire.comSee More Aethlon Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aethlon Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aethlon Medical and other key companies, straight to your email. Email Address About Aethlon MedicalAethlon Medical (NASDAQ:AEMD) (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings. The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components. Aethlon has advanced the device through human clinical trials, exploring its potential in patients with viral infections—such as hepatitis C and COVID-19—and in oncology patients where tumor‐derived exosomes contribute to immune system evasion. The company continues to refine its technology, pursue regulatory designations, and seek strategic collaborations to expand its clinical development efforts. Headquartered in San Diego, California, Aethlon Medical was established with a mission to bring innovative extracorporeal therapies to market. Under the leadership of President and Chief Executive Officer Phillip D. Borden, the company engages with regulatory agencies and research institutions across North America and internationally. Aethlon’s research and development operations are complemented by partnerships aimed at accelerating the clinical evaluation of its platform and ultimately delivering new treatment options for patients with urgent medical needs.View Aethlon Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareIntel Earnings Reveal Whether the Chip Selloff Created a BuyDefense Earnings Show Readiness Now and Modernization AheadFreeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good EnoughTesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Upcoming Earnings Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026)Rio Tinto (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
